Dynein axonemal heavy chain 9 (DNAH9)
Homo sapiens — UniProt Q9NYC9
Gene: DNAH9Homo sapiensSwissProt reviewed
Data last refreshed: (UniProt release unknown)
Key facts
Dynein axonemal heavy chain 9 (DNAH9) is a protein from Homo sapiens identified by UniProt accession Q9NYC9, 4486 residues long. MolForge cross-references it against 0 known binders and 78 disease associations.
- UniProt accession: Q9NYC9; gene symbol DNAH9.
- Organism: Homo sapiens.
- Length: 4486 amino acids.
- Top disease associations (Open Targets): ciliary dyskinesia, primary, 40, primary ciliary dyskinesia and congenital heart disease.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Dynein axonemal heavy chain 9 |
|---|---|
| UniProt accession | Q9NYC9 |
| Gene | DNAH9 |
| Organism | Homo sapiens |
| Length | 4486 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (78)
Diseases linked to this target (Open Targets).
- ciliary dyskinesia, primary, 40 · score 0.77
- primary ciliary dyskinesia · score 0.50
- congenital heart disease · score 0.42
- Situs inversus totalis · score 0.37
- visceral heterotaxy · score 0.37
- Non-immune hydrops fetalis · score 0.34
- Hydrocephalus · score 0.32
- gut microbiome measurement · score 0.27
- genetic disorder · score 0.19
- Abnormal cardiovascular system morphology · score 0.15
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9NYC9-F9 | alphafold | PREDICTED | 89.73 | — |
| AF-Q9NYC9-F8 | alphafold | PREDICTED | 87.99 | — |
| AF-Q9NYC9-F11 | alphafold | PREDICTED | 87.33 | — |
| AF-Q9NYC9-F17 | alphafold | PREDICTED | 87.27 | — |
| AF-Q9NYC9-F10 | alphafold | PREDICTED | 87.14 | — |
| AF-Q9NYC9-F7 | alphafold | PREDICTED | 87.03 | — |
| AF-Q9NYC9-F15 | alphafold | PREDICTED | 86.39 | — |
| AF-Q9NYC9-F5 | alphafold | PREDICTED | 85.58 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9NYC9.
Amino-acid sequence (4486 residues)
MRLAEERAAL AAENADGEPG ADRRLRLLGT YVAMSLRPAA GAWERCAGSA EAEQLLQAFL GRDAAEGPRP LLVVRPGPRG LAIRPGLEVG PESGLAGAKA LFFLRTGPEP PGPDSFRGAV VCGDLPAAPL EHLAALFSEV VLPVLANEKN RLNWPHMICE DVRRHAHSLQ CDLSVILEQV KGKTLLPLPA GSEKMEFADS KSETVLDSID KSVIYAIESA VIKWSYQVQV VLKRESSQPL LQGENPTPKV ELEFWKSRYE DLKYIYNQLR TITVRGMAKL LDKLQSSYFP AFKAMYRDVV AALAEAQDIH VHLIPLQRHL EALENAEFPE VKPQLRPLLH VVCLIWATCK SYRSPGRLTV LLQEICNLLI QQASNYLSPE DLLRSEVEES QRKLQVVSDT LSFFKQEFQD RRENLHTYFK ENQEVKEWDF QSSLVFVRLD GFLGQLHVVE GLLKTALDFH KLGKVEFSGV RGNALSQQVQ QMHEEFQEMY RLLSGSSSDC LYLQSTDFEN DVSEFNQKVE DLDRRLGTIF IQAFDDAPGL EHAFKLLDIA GNLLERPLVA RDTSDKYLVL IQMFNKDLDA VRMIYSQHVQ EEAELGFSPV HKNMPTVAGG LRWAQELRQR IQGPFSNFGR ITHPCMESAE GKRMQQKYED MLSLLEKYET RLYEDWCRTV SEKSQYNLSQ PLLKRDPETK EITINFNPQL ISVLKEMSYL EPREMKHMPE TAAAMFSSRD FYRQLVANLE LMANWYNKVM KTLLEVEFPL VEEELQNIDL RLRAAEETLN WKTEGICDYV TEITSSIHDL EQRIQKTKDN VEEIQNIMKT WVTPIFKTKD GKRESLLSLD DRHDRMEKYY NLIKESGLKI HALVQENLGL FSADPTSNIW KTYVNSIDNL LLNGFFLAIE CSLKYLLENT ECKAGLTPIF EAQLSLAIPE LVFYPSLESG VKGGFCDIVE GLITSIFRIP SLVPRLSPQN GSPHYQVDLD GIPDLANMRR TLMERVQRMM GLCCGYQSTF SQYSYLYVED RKEVLGQFLL YGHILTPEEI EDHVEDGIPE NPPLLSQFKV QIDSYETLYE EVCRLEPIKV FDGWMKIDIR PFKASLLNII KRWSLLFKQH LVDHVTHSLA NLDAFIKKSE SGLLKKVEKG DFQGLVEIMG HLMAVKERQS NTDEMFEPLK QTIELLKTYE QELPETVFKQ LEELPEKWNN IKKVAITVKQ QVAPLQANEV TLLRQRCTAF DAEQQQFWEQ FHKEAPFRFD SIHPHQMLDA RHIEIQQMES TMASISESAS LFEVNVPDYK QLRQCRKEVC QLKELWDTIG MVTSSIHAWE TTPWRNINVE AMELECKQFA RHIRNLDKEV RAWDAFTGLE STVWNTLSSL RAVAELQNPA IRERHWRQLM QATGVSFTMD QDTTLAHLLQ LQLHHYEDEV RGIVDKAAKE MGMEKTLKEL QTTWAGMEFQ YEPHPRTNVP LLCSDEDLIE VLEDNQVQLQ NLVMSKYVAF FLEEVSGWQK KLSTVDAVIS IWFEVQRTWT HLESIFTGSE DIRAQLPQDS KRFEGIDIDF KELAYDAQKI PNVVQTTNKP GLYEKLEDIQ GRLCLCEKAL AEYLDTKRLA FPRFYFLSSS DLLDILSNGT APQQVQRHLS KLFDNMAKMR FQLDASGEPT KTSLGMYSKE EEYVAFSEPC DCSGQVEIWL NHVLGHMKAT VRHEMTEGVT AYEEKPREQW LFDHPAQVAL TCTQIWWTTE VGMAFARLEE GYESAMKDYY KKQVAQLKTL ITMLIGQLSK GDRQKIMTIC TIDVHARDVV AKMIAQKVDN AQAFLWLSQL RHRWDDEVKH CFANICDAQF LYSYEYLGNT PRLVITPLTD RCYITLTQSL HLTMSGAPAG PAGTGKTETT KDLGRALGIL VYVFNCSEQM DYKSCGNIYK GLAQTGAWGC FDEFNRISVE VLSVVAVQVK SIQDAIRDKK QWFSFLGEEI SLNPSVGIFI TMNPGYAGRT ELPENLKSLF RPCAMVVPDF ELICEIMLVA EGFIEAQSLA RKFITLYQLC KELLSKQDHY DWGLRAIKSV LVVAGSLKRG DPDRPEDQVL MRSLRDFNIP KIVTDDMPIF MGLIGDLFPA LDVPRRRDPN FEALVRKAIV DLKLQAEDNF VLKVVQLEEL LAVRHSVFVV GGAGTGKSQV LRSLHKTYQI MKRRPVWTDL NPKAVTNDEL FGIINPATGE WKDGLFSSIM RELANITHDG PKWILLDGDI DPMWIESLNT VMDDNKVLTL ASNERIPLNP TMKLLFEISH LRTATPATVS RAGILYINPA DLGWNPPVSS WIEKREIQTE RANLTILFDK YLPTCLDTLR TRFKKIIPIP EQSMVQMVCH LLECLLTTED IPADCPKEIY EHYFVFAAIW AFGGAMVQDQ LVDYRAEFSK WWLTEFKTVK FPSQGTIFDY YIDPETKKFE PWSKLVPQFE FDPEMPLQAC LVHTSETIRV CYFMERLMAR QRPVMLVGTA GTGKSVLVGA KLASLDPEAY LVKNVPFNYY TTSAMLQAVL EKPLEKKAGR NYGPPGNKKL IYFIDDMNMP EVDAYGTVQP HTIIRQHLDY GHWYDRSKLS LKEITNVQYV SCMNPTAGSF TINPRLQRHF SVFVLSFPGA DALSSIYSII LTQHLKLGNF PASLQKSIPP LIDLALAFHQ KIATTFLPTG IKFHYIFNLR DFANIFQGIL FSSVECVKST WDLIRLYLHE SNRVYRDKMV EEKDFDLFDK IQTEVLKKTF DDIEDPVEQT QSPNLYCHFA NGIGEPKYMP VQSWELLTQT LVEALENHNE VNTVMDLVLF EDAMRHVCHI NRILESPRGN ALLVGVGGSG KQSLTRLAAF ISSMDVFQIT LRKGYQIQDF KMDLASLCLK AGVKNLNTVF LMTDAQVADE RFLVLINDLL ASGEIPDLYS DDEVENIISN VRNEVKSQGL VDNRENCWKF FIDRIRRQLK VTLCFSPVGN KLRVRSRKFP AIVNCTAIHW FHEWPQQALE SVSLRFLQNT EGIEPTVKQS ISKFMAFVHT SVNQTSQSYL SNEQRYNYTT PKSFLEFIRL YQSLLHRHRK ELKCKTERLE NGLLKLHSTS AQVDDLKAKL AAQEVELKQK NEDADKLIQV VGVETDKVSR EKAMADEEEQ KVAVIMLEVK QKQKDCEEDL AKAEPALTAA QAALNTLNKT NLTELKSFGS PPLAVSNVSA AVMVLMAPRG RVPKDRSWKA AKVTMAKVDG FLDSLINFNK ENIHENCLKA IRPYLQDPEF NPEFVATKSY AAAGLCSWVI NIVRFYEVFC DVEPKRQALN KATADLTAAQ EKLAAIKAKI AHLNENLAKL TARFEKATAD KLKCQQEAEV TAVTISLANR LVGGLASENV RWADAVQNFK QQERTLCGDI LLITAFISYL GFFTKKYRQS LLDRTWRPYL SQLKTPIPVT PALDPLRMLM DDADVAAWQN EGLPADRMSV ENATILINCE RWPLMVDPQL QGIKWIKNKY GEDLRVTQIG QKGYLQIIEQ ALEAGAVVLI ENLEESIDPV LGPLLGREVI KKGRFIKIGD KECEYNPKFR LILHTKLANP HYQPELQAQA TLINFTVTRD GLEDQLLAAV VSMERPDLEQ LKSDLTKQQN GFKITLKTLE DSLLSRLSSA SGNFLGETVL VENLEITKQT AAEVEKKVQE AKVTEVKINE AREHYRPAAA RASLLYFIMN DLSKIHPMYQ FSLKAFSIVF QKAVERAAPD ESLRERVANL IDSITFSVYQ YTIRGLFECD KLTYLAQLTF QILLMNREVN AVELDFLLRS PVQTGTASPV EFLSHQAWGA VKVLSSMEEF SNLDRDIEGS AKSWKKFVES ECPEKEKLPQ EWKNKTALQR LCMLRAMRPD RMTYALRDFV EEKLGSKYVV GRALDFATSF EESGPATPMF FILSPGVDPL KDVESQGRKL GYTFNNQNFH NVSLGQGQEV VAEAALDLAA KKGHWVILQN IHLVAKWLST LEKKLEEHSE NSHPEFRVFM SAEPAPSPEG HIIPQGILEN SIKITNEPPT GMHANLHKAL DNFTQDTLEM CSRETEFKSI LFALCYFHAV VAERRKFGPQ GWNRSYPFNT GDLTISVNVL YNFLEANAKV PYDDLRYLFG EIMYGGHITD DWDRRLCRTY LGEFIRPEML EGELSLAPGF PLPGNMDYNG YHQYIDAELP PESPYLYGLH PNAEIGFLTQ TSEKLFRTVL ELQPRDSQAR DGAGATREEK VKALLEEILE RVTDEFNIPE LMAKVEERTP YIVVAFQECG RMNILTREIQ RSLRELELGL KGELTMTSHM ENLQNALYFD MVPESWARRA YPSTAGLAAW FPDLLNRIKE LEAWTGDFTM PSTVWLTGFF NPQSFLTAIM QSTARKNEWP LDQMALQCDM TKKNREEFRS PPREGAYIHG LFMEGACWDT QAGIITEAKL KDLTPPMPVM FIKAIPADKQ DCRSVYSCPV YKTSQRGPTY VWTFNLKTKE NPSKWVLAGV ALLLQI
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which diseases are associated with DNAH9?
The strongest Open Targets associations for DNAH9 are ciliary dyskinesia, primary, 40, primary ciliary dyskinesia, congenital heart disease, Situs inversus totalis and visceral heterotaxy.
How long is the DNAH9 protein?
The Homo sapiens DNAH9 protein (UniProt Q9NYC9) is 4486 amino acids long.
Browse: Targets: D · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9NYC9 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9NYC9 — predicted 3D structure (CC BY 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.